What to do next? is a question many young, aspiring pharmaceutical scientists ask themselves as they progress in their education or early on in their careers. This webinar aims to inspire participants that are considering an academic career by showcasing two pharmaceutical researchers who have chosen an academic career. The speakers will reveal what was their motivation and how they navigated to their current position, what from their education was most valuable to their current career, and what experiences they have gained along the way.

Learning objectives:
- Participants will be able to compare an academic career in two different regions.
- Participants will learn what was required for the two speakers to reach their current role and use this to plan their own career.
- Participants will gain insights from the speakers on how to design/fulfill the key steps that make an early career researcher stand out.

Moderators:
- Sifei Han, NHMRC Early Career Fellow, Drug Delivery Disposition & Dynamics, Monash University - Australia
- Sarah Dineen-Griffin, Lecturer, Health Services Management, School of Biomedical Sciences, Charles Sturt University - Australia

Panellists:
- Stephanie Reuter Lange, Cancer Council Mid Career Research Fellow, University of South Australia - Australia
- Lirui Wang, Professor, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University - China

Generic drugs provide significant public health benefits by providing high-quality, more affordable alternatives to brand name drugs. Approximately 90 percent of prescriptions dispensed in the United States are generic drugs that often are the product of an intricate global supply chain. The Office of Generic Drugs (OGD) is involved in
efforts to advance the international harmonization of scientific, technical and regulatory standards for generic drug development. The outcome of these global efforts is reduced time and cost of product development, consequently improving patient access to more affordable medicines. FDA’s efforts at international harmonization of standards for generic drugs will be reviewed. The financial impact of this harmonization on development costs and consequent easier access for patients to generic drugs will be discussed. The harmonization efforts would help regulatory agencies in the timely approval of generic drugs thereby accelerating access to affordable, safe, effective, and high-quality generic medicines for the American public.

Learning Objectives:
- Financial impact of harmonized international standards on global access to less expensive medications
- FDA’s operational modalities for generic drug approvals
- FDA’s efforts at international harmonization of scientific, technical and regulatory standards

Moderator:
- Mathew Cherian, ExCo Member, Industrial Pharmacy Section, FIP -

Panellists:
- Sarah Ibrahim, Associate Director, FDA, Center for Drug Evaluation and Research (CDER) - USA